




RealRate

PHARMACEUTICAL 2016

ANI Pharmaceuticals INC
Rank 143 of 295



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of ANI Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANI Pharmaceuticals INC compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 45% points. The greatest weakness of ANI Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 112% points.

The company's Economic Capital Ratio, given in the ranking table, is 287%, being 24% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	192,583
Cost of Goods Sold	12,692
Intangible Assets	68,235
Liabilities, Current	11,756
Liabilities, Non-Current	0
Other Assets	17,316
Other Compr. Net Income	0
Other Expenses	13,258
Other Liabilities	113,427
Other Net Income	-10,967
Other Revenues	76,322
Property and Equipment	7,131
Research and Development	2,874
Selling, General and Administrative Expense	21,156

Output Variable	Value in 1000 USD
Assets	285,265
Liabilities	125,183
Expenses	49,980
Revenues	76,322
Stockholders Equity	160,082
Net Income	15,375
Comprehensive Net Income	15,375
BaseVar	273,858
ECR before LimitedLiability	178%
Economic Capital Ratio	287%